Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial

Ann Oncol. 2021 Jan;32(1):120-121. doi: 10.1016/j.annonc.2020.10.474. Epub 2020 Oct 21.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Fibroblasts
  • Humans
  • Lung Neoplasms* / drug therapy
  • Mesothelioma* / drug therapy
  • Mesothelioma, Malignant*
  • Pleural Neoplasms* / drug therapy
  • T-Lymphocytes